Expression of BAX in plasma cell dyscrasias

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2371-2380

  Renner, Stephen ^a   Weisz, Jeffrey ^b,c   Krajewski, Stanislaw ^d   Krajewska, Maryla ^d   Reed, John C ^d   Lichtenstein, Alan ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

^d BURNHAM INSTITUTE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; MELPHALAN; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; VINCRISTINE;

ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PLASMACYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; BLOTTING, WESTERN; BONE MARROW; CELL DIVISION; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; MELPHALAN; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS; PREDNISONE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; TIME FACTORS; VINCRISTINE;

EID: 0034125878     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Reed, J. C. BCL-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv. Pharmacol., 41: 501-507, 1997.
2. Campos, L., Roualt, J-P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J-P., and Guyotat, D. High expression of BCL-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81: 3091-3098, 1993.
3. Maung, Z. T., MacLean, F. R., Reid, M. M., Pearson, A. D. J., Proctor, S. J., Hamilton, P. J., and Hall, A. G. The relationship between BCL-2 expression and response to chemotherapy in acute leukemia. Br. J. Haematol., 88: 105-109, 1994.
4. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. BCL-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690-695, 1993.
5. Herod, J. J. O., Eliopoulos, A. G., Warwick, J., Niedobitek, G., Young, L., and Kerr, D. J. The prognostic significance of BCL-2 and p53 expression in ovarian carcinoma. Cancer Res., 56: 2178-2184, 1996.
6. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V-M., Niskanen, E., Nordling, S., and Reed, J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic adenocarcinoma. Cancer Res., 55: 4471-4480, 1995.
7. Thomas, A., El Rouby, S., Reed, J. C., Krajewski, S., Silber, R., Potmesil, M., and Newcomb, E. W. Drug-induced apoptosis in B cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene, 12: 1055-1061, 1996.
8. Pettersson, M., Jernberg-Wiklund, H., Larsson, L-G., Sundstrom, C., Givol, I., Tsujimoto, Y., and Nilsson, K. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood, 79: 495-501, 1992.
9. Sangfelt, O., Osterborg, A., Grander, D., Anderbring, E., Ost, A., Mellstedt, H., and Einhorn, S. Response to interferon therapy in patients with multiple myeloma correlates with expression of the bcl-2 oncoprotein. Int. J. Cancer, 63: 190-197, 1995.
10. Ong, F., Nieuwkoop, J. A., von de Groot-Swings, G. M. J. S., Hermans, J., Harvey, M. S., Kluin, P. H. M., and Kluin-Neklemans, J. C. BCL-2 protein expression is not related to short survival in multiple myeloma. Leukemia (Baltimore), 9: 1282-1290, 1995.
11. Durie, B. G. M., Mason, D. Y., Giles, F., Vela, E. E., Knight, I., Wolff, S., Foadi, M., and Samson, D. Expression of the BCL-2 oncogene protein in multiple myeloma. Blood, 76: 347a, 1990.
12. Hamilton, M. S., Barker, H. F., Ball, J., Drew, M., Abbot, S. D., and Franklin, I. M. Normal and neoplastic human plasma cells express BCL-2 antigen. Leukemia (Baltimore), 5: 768-774, 1991.
13. Mariano, M. T., Moretti, L., Donelli, A., Grantini, M., Montagnani, G., Di Prisco, A. U., Torelli, G., Torelli, U., and Narni, F. BCL-2 gene expression in hematopoietic cell differentiation. Blood, 80: 768-775, 1992.
14. Tu, Y., Renner, S., Xu, F-H., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C., and Lichtenstein, A. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res., 58: 256-262, 1998.
15. Catlett-Falcone, R., Landowski, T., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W., and Jove, R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999.
16. Puthier, D., Pellat-Deceunynck, C., Barille, S., Robillard, N., Rapp, M-J., Juge-Morineau, N., Harousseau, J-L., Bataille, R, and Amiot, M. Differential expression of BCL-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia (Baltimore), 13: 289-294, 1999.
17. Egle, A., Villunger, A., Marschitz, I., Kos, M., Hittmain, A., Lukas, P., Grunewald, K., and Greil, R. Expression of fas (CD95), BCL-2, BAX and BCL-X in myeloma cell lines: relationship between responsiveness to anti-fas Mab and p53 functional status. Br. J. Haematol., 97: 418, 1997.
18. Committee of the Chronic Leukemia-Myeloma Task Force; National Cancer Institute. Cancer Chemother. Rep., 4: 145-153, 1973.
19. Kyle, R. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am. J. Med., 64: 814-823, 1978.
20. Alexanian, R. Localized and indolent myeloma. Blood, 56: 521-529, 1980.
21. Kroning, R., and Lichtenstein, A. Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis. Leuk. Res., 22: 275-282, 1998.
22. Xu, F-H., Gardner, A., Tu, Y., Michl, P., Prager, D., and Lichtenstein, A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br. J. Haematol., 97: 429-440, 1997.
23. Krajewska, M., Fenoglio-Preiser, C. M., Krajewski, S., Song, K., Macdonald, J. S., Stemmerman, G., and Reed, J. C. Immunohistochemical analysis of BCL-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol., 149: 1449-1458, 1996.
24. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R, and Berenson, J. IL-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-255, 1995.
25. Ogata, A., Chauhan, D., Teoh, G, Treon, S. P., Urashima, M., Schlossman, R. L., and Anderson, K. L. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J. Immunol., 759: 2212-2221, 1997.
26. Xu, F-H., Sharma, S., Gardner, A., Tu, Y., Raitano, A., Sawyers, C., and Lichtenstein, A. IL-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood, 92: 241-251, 1998.
27. Daeipour, M., Kumar, G, Amaral, M. C., and Nel, A. E. Recombinant IL-6 activates p42 and p44 mitogen-activated kinases in the IL-6-responsive B cell line AF-10. J. Immunol., 150: 4743-4751, 1993.
28. Brady, H. J. M., Gil-Gomez, G., and Kirberg, J. BAX-α perturbs T cell development and affects cell cycle entry of T cells. EMBO J., 15: 6991-7000, 1996.
29. Miguel-Garcia, A., Orero, T., and Matutes, E. BCL-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica, 83: 298-304, 1998.
30. Landanyi, M., Wang, S., Niesvizky, R., Feiner, H., and Michaeli, J. Proto-oncogene analysis in multiple myeloma. Am. J. Pathol., 141: 949-957, 1992.
31. Miyashita, T., Krajewski, S., Krajewski, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1807, 1994.
32. Neri, A., Baldini, L., and Trecca, D. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood, 81: 128-136, 1993.
33. Monni, O., Jensuu, H., Fransilla, K., Klefstrom, J., Alitalo, K., and Knuutila, S. BCL-2 overexpression associated with chromosomal amplification in diffuse large B cell lymphoma. Blood, 90: 1168-1175, 1997.
34. Miyashita, T., Kitada, S., and Krajewski, S. Over-expression of the BCL-2 protein increases the half-life of p21BAX. J. Biol. Chem., 270: 26049-26058, 1995.
35. Tu, Y., Xu, F-H., Liu, J., Vesio, R., Berensin, J., Fady, C., and Lichtenstein, A. Up-regulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood, 88: 1805-1812, 1996.
36. Binder, C., Marx, D., Binder, L., Schauer, A., and Hiddemann, W. Expression of BAX in relation to BCL-2 and other predictive parameters in breast cancer. Ann. Oncol., 7: 129-137, 1996.
37. Marx, D., Binder, C., Meden, H., Lenthe, T., Ziemek, T., Hiddemann, T., Kuhn, W., and Schauer, A. Differential expression of apoptosis associated genes BAX and BCL-2 in ovarian cancer. Anticancer Res., 17: 2233-2240, 1997.
38. Apolinario, R. M., van der Valk, P., de Jong, J. S., Deville, W., van Ark-Otte, J., Dingemans, A. M., van Mourik, J. C., Postmus, P. E., Pinedo, H. M., and Giaccone, G. Prognostic value of the expression of p53, BCL-2 and BAX oncoproteins and neovascularization in patients with radically resected non-small cell lung cancer. J. Clin. Oncol., 15: 2456-2466, 1997.
39. Gascoyne, R. D., Krajewska, M., Krajewski, S., Connors, J. M., and Reed, J. C. Prognostic significance of BAX protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood, 90: 3173-3178, 1997.
40. O'Reilly, L., Harris, A. W., Tarlinton, D. M., Corcoran, L. M., and Strasser, A. Expression of a BCL-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J. Immunol., 159: 2301-2311, 1997.
41. van Slooten, H-J., van de Vijver, M. J., van de Velde, C. J. H., and van Dierendonck, J. H. Loss of BCL-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br. J. Cancer, 77: 789-796, 1998.
42. Wilson, W. H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S. M., Jaffe, E. S., and Raffield, M. Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89: 601-610, 1997.
43. Lokhorst, H. M., Boom, S., Terpstra, W., Roholl, P., Gerdes, J., and Bast, B. J. E. G. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br. J. Haematol., 49: 477-481, 1988.
44. Drach, J., Gattringer, C., Glassl, H., Drach, D., and Huber, H. The biological and clinical significance of the Ki-67 growth fraction in multiple myeloma. Hematol. Oncol., 10: 125-134, 1992.